Jazz Pharmaceuticals Stock (NASDAQ:JAZZ)

USA |NASDAQ |USD

Price
$122.70
Change
1.27%
Today's Range
$120.34 - $123.67
52-Week Range
$117.64 - $189.00
Market Cap
$7.52B
Volume
386.62K

About Jazz Pharmaceuticals (NASDAQ:JAZZ)

(NASDAQ:JAZZ)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also offers JZP-258, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for some narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and lurbinectedin, a product candidate under clinical investigation for the treatment of patients with relapsed small cell lung cancer. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.

Show more

JAZZ Stock Price

Statistics Highlights (NASDAQ:JAZZ)

Shares Outstanding 61.47M Beta 0.91
Public Float 59.89M P/E Ratio -
% Short of Float - Dividend (Yield) -
Held by Insiders 2.56% Ex-Dividend Date
Held by Institutions 96.91% IPO Date Jun 1, 2007

JAZZ Financial Summary

|
Dec 20 Dec 19 Dec 18
Revenue $2.36B $2.16B $1.89B
EBITDA $631.42M $892.63M $821.07M
Net Income $238.62M $523.37M $447.10M
Total Assets $6.54B $5.54B $5.20B
Total Cash $1.06B $333.17M $215.61M
Total Debt $2.11B $1.62B $1.60B
Sep 21 Jun 21 Mar 21
Revenue $838.12M $751.81M $607.58M
EBITDA $190.06M $82.04M $240.20M
Net Income $-52.83M $-363.32M $121.83M
Total Assets $12.48B $13.21B $6.76B
Total Cash $671.78M $891.40M $2.10B
Total Debt $6.38B $6.92B $2.25B

(NASDAQ:JAZZ) Stock Price FAQs

What is today's stock price of Jazz Pharmaceuticals (NASDAQ:JAZZ)?

  • The current stock price of Jazz Pharmaceuticals (NASDAQ:JAZZ) is $122.70.
  • Today JAZZ stock price opened at $121.30 after previous close of $121.16.
  • During the day, Jazz Pharmaceuticals stock quote has varied from a low of $120.34 to a high of $123.67.

What is Jazz Pharmaceuticals's 52-week change?

  • JAZZ 52-week high stock quote is $189.00, which is 54.00% above the current share price.
  • The Jazz Pharmaceuticals (NASDAQ:JAZZ) 52-week low stock price is $117.64, which is 4.10% below the current share price.
  • Jazz Pharmaceuticals share price volatility (52-week beta) is 0.91.

Is Jazz Pharmaceuticals a buy?

  • According to 20 analysts, the current consensus recommendation for Jazz Pharmaceuticals stock is "Buy" at an average rating score of 4.45 (out of 5).
  • There are currently 12 "Strong Buy", 6 "Buy", 1 "Hold", 1 "Sell", and 0 "Strong Sell" analysts recommendations for the JAZZ stock.
  • The 12 month average price target forecast for JAZZ stock is $181.74, representing a 48.10% increase from the current JAZZ stock price of $122.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) FAQ

How Much is Jazz pharmaceuticals Worth?

Jazz pharmaceuticals's worth today based on market capitalisation is $7.52B

How much money does Jazz pharmaceuticals make?

Last quarter (ended on September 30 ,2021) Jazz pharmaceuticals generated a net income of $-52.83M, representing a 380.57% decrease compared to the same quarter a year before (ended on September 30 ,2020).
Last fiscal year (ended on December 31 ,2020) Jazz pharmaceuticals generated a net income of $238.62M, representing a 54.41% decrease compare to the previous fiscal year (ended on December 31 ,2019).
View More Details on Jazz pharmaceuticals's “Financials” Section

How much dividend does Jazz pharmaceuticals Pay?

The current annualized dividend payout for JAZZ stock is $0.00, the dividend yield is 0.00% and the payout ratio is 0.00%.
View More Details on Jazz pharmaceuticals's "Dividend" Section

What were Jazz pharmaceuticals’s last Earnings results?

For the last quarterly earnings period (ended on September 30, 2021) JAZZ reported $4.20 EPS for the quarter, beating the average analysts’ forecasts of $3.31 EPS by $0.89 (26.71%).
View More Details on Jazz pharmaceuticals's 'Earnings' Section

When is the next earnings date for Jazz pharmaceuticals (NASDAQ:JAZZ)?

Jazz pharmaceuticals is expected to report earnings on February 21 ,2022.
View More Details on Jazz pharmaceuticals's 'Earnings' Section

What is Jazz pharmaceuticals’s Price to Earning (PE) ratio?

JAZZ stock also has a Price to Sales (P/S) ratio of 2.63, a Price to Book of 1.91 and Price/Earnings to Growth (PEG) of 4.98.

What is the Jazz pharmaceuticals's ticker?

Jazz pharmaceuticals trades on the NASDAQ stock market in USA under the ticker symbol "JAZZ". Jazz pharmaceuticals’s stock symbol can also be displayed as "NASDAQ:JAZZ".

When did JAZZ go public?

Jazz pharmaceuticals completed its initial public offering (IPO) on June 01 ,2007.

Who are the owners of Jazz pharmaceuticals?

Jazz pharmaceuticals (NASDAQ:JAZZ) is owned by 96.91% institutional shareholders and by 2.56% insiders. The rest is owned by the public.
The 3 top institutional shareholders are "BlackRock Inc", "Vanguard Group Inc" and "FMR Inc", representing 24.59% of Jazz pharmaceuticals’s total shares outstanding.
Explore More Details on Jazz pharmaceuticals's “Ownership” Section

Who are the key executives of Jazz pharmaceuticals (JAZZ)?

Jazz pharmaceuticals's key executive team includes the following managers:

  • Mr. Bruce C. Cozadd, Co-Founder, Chairman & CEO (1964)
  • Mr. Daniel N. Swisher Jr., Pres (1963)
  • Ms. Renee D. Gala, Exec. VP & CFO (1972)
  • Dr. Robert Iannone M.D., Exec. VP of R&D and Chief Medical Officer (1967)
  • Ms. Kim Sablich, Exec. VP & GM of North America (1969)
  • Mr. Christopher John Tovey, Exec. VP, COO and MD of Europe & International (1965)
  • Ms. Patricia Carr, VP of Fin. & Principal Accounting Officer (1971)
  • Dr. Finbar Larkin Ph.D., Sr. VP of Technical Operations (1958)
  • Ms. Andrea N. Flynn, VP & Head of Investor Relations (NA)
  • Ms. Neena M. Patil J.D., Chief Legal Officer and Sr. VP of Legal & Corp. Affairs (1975)

What is Jazz pharmaceuticals’s Sector & Industry Classification?

Jazz pharmaceuticals (NASDAQ:JAZZ) is classified under the "Healthcare" sector and under the "Biotechnology" industry.

What is the ESG rating for Jazz pharmaceuticals (NASDAQ:JAZZ) ?

ESG scores assess the degree to which a company’s enterprise business value is at risk driven by environmental, social, and governance issues. The scores are a measure of risk on an absolute scale of 0-100, with a lower score meaning less risk.

JAZZ’s total ESG score is 31.66. The company’s environmental score is 4.18, social score is 24.74 and governance score is 13.74.
Jazz pharmaceuticals (NASDAQ:JAZZ) is involved in the following activities (which decreases its ESG score) : "animalTesting".

How many employees work for Jazz pharmaceuticals?

Currently the number of employees working for Jazz pharmaceuticals is 1,940.

Where are Jazz pharmaceuticals's Headquarters?

Jazz pharmaceuticals (NASDAQ:JAZZ) is headquartered in Ireland.

What are Jazz pharmaceuticals's Address and Phone Number?

Jazz pharmaceuticals’s mailing address is Waterloo Exchange, Dublin, Ireland, 4.
The company’s phone number is 353 1 634 7800.

What is the official website for Jazz pharmaceuticals?

Jazz pharmaceuticals’s official website is http://www.jazzpharma.com